The prospective project MOSAR was conducted in five rehabilitation units: BM (France), FS predominates among ESBLs (13, 30, 35, 42, 43 Species identification was done with the Vitek 2 system (bioMérieux, Marcy l'Etoile, France).
per hospital; differences in numbers between particular sites resulted from differences in 112 timing of the clinical trials at the sites, availability of cultures at the start of this analysis, and 113 the overall number of ESC-resistant isolates at each institution. The majority of isolates from 114 TA were used also in a separate study on colonization risk factors and population dynamics of 115 ESBL-positive E. coli, and a part of the molecular data is presented elsewhere (1).
116
Typing. Pulsed-field gel electrophoresis (PFGE) was performed as described (46), with the 117 use of the XbaI restriction enzyme (Fermentas, Vilnius, Lithuania) . PFGE types and subtypes 118 were discerned visually using the Tenover et al.'s criteria (48) . In order to construct 119 dendrograms, electrophoretic patterns were compared by the BioNumerics Fingerprinting 120 software (Version 6.01, Applied Maths, Sint-Martens-Latem, Belgium), using the Dice 121 coefficient and clustering by unweighted pair group method with arithmetic mean, with 1% 122 tolerance in band position differences. Multilocus sequence typing (MLST) was carried out as 123 described previously (53); the database available at http://mlst.ucc.ie was used for assigning 124 sequence types (STs) and clonal complexes. The clonal diversity indexes and confidence 125 intervals (CI) were calculated according to Grundmann et al. (22) . Classification of isolates 126 into major E. coli phylogenetic groups was done by PCR (10).
127
β-Lactamase analysis. β-lactamase profiling was done by isoelectric focusing as reported (2), 128 using a Model 111 Mini IEF Cell (Bio-Rad, Hercules, CA). Identification of the bla CTX-M-1 -, 129 bla CTX-M-2 -, bla CTX-M-9 -, bla CTX-M-25 -, bla SHV -, bla TEM -, bla CMY-2 -and bla DHA -like genes was 130 done by PCRs (17, 18, 29, 54) . Sequencing of the genes was performed as reported (17) were differentiated; however, the on-going spread of specific strains likely played a notable 142 role as well. Indeed, the detailed analysis (PFGE and β-lactamase profiling) revealed clusters 143 of closely related isolates in each center, most significantly in FS and TA (discussed below).
144
"Major" clones. Twenty-two clones were observed in at least two centers in different 145 countries (n=292; 77.7%), while 10 STs were identified in three or more hospitals each (Table   146 1). Of these 10 clones, seven comprised at least 10 isolates each, namely STs:10, 38, 69, 131, 147 405, 410 and 648, accounting for 65.2% of the study isolates (n=245). The situation in which 148 a large collection of E. coli isolates is dominated by a small number of clones was often 149 observed but the composition of such groups differed according to the region, and type and 150 source of isolates (20, 28, 39, 49 were reported in many works performed world-wide on isolates from hospital and community 153 patients (5, 19, 20, 39, 49, 55) . Their isolates varied inter-and intra-clonally in virulence (5, 154 20, 26, 50, 53) ; recently they have been often associated with diverse resistance traits,
155
including ESBLs and other β-lactamases (5, 15, 19, 20, 26, 32, 33, 38, 39, 49, 55 including several types of ST131 (e. g. TAEcoI), and some types of STs: 38, 69, 405 and 648. 206 In all these cases isolates of the same PFGE type produced the same β-lactamase in both 207 institutions (see below). The PFGE heterogeneity of ST131 and efficient spread of specific 208 types have been observed previously, and it seems that while in general the diversity reflects 209 the long-term evolution of the clone, the prevalent PFGE types may represent emerging 210 subclones with even enhanced epidemic potential (25, 27, 39 ESBLs belonged to CTX-M (n=303; 79.9%), SHV (n=51; 13.5%) and TEM (n=4; 1.1%) 220 families, while AmpCs were CMY-2-like enzymes (n=20; 5.3%) and DHA-1 (n=1; 0.3%).
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The prevalence of CTX-Ms was 66.7% in GI, 69.2% in LH, 77.3% in TA, 78.1% in BM and (39.4%). CTX-M-27 and CTX-M-1 were observed in three centers each, and were produced 233 by 42 and 30 isolates, respectively (11.1% and 7.9% of all of the enzymes, respectively).
234
CTX-M-27 was prevalent in TA (24.8%) but it was expressed only by three STs; in contrast, CTX-M-1, frequent in FS (23.1%), was produced by 26 clones. CTX-M-100 from a single 236 isolate from TA, was a new CTX-M-25-like variant, described in details separately (51).
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All these results reflected well the rapid dissemination of the CTX-M-type enzymes in the last c -E. coli phylogroups were adopted from Refs. 3, 31, 37 or 55 (STs: 10, 38, 57, 59, 69, 117, 131, 155, 354, 405, 410, 648) or determined in this 491 work (STs: 48, 88, 167, 216, 224, 617, 744, 929, 940, 1431) 
